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Abstract
Background—Amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) is a 
neurodegenerative disease that results in progressive muscle weakness and wasting. There is no 
known cure and the disease is uniformly fatal.
Purpose—This review discusses current concepts in ALS care, from breaking the diagnosis to 
end-of-life care. People with ALS have several multidisciplinary needs due to a complex and 
dynamic disease process. They benefit from rehabilitation interventions that are individualized and 
have the goal of optimizing independence, function, and safety. These strategies also help 
minimize symptomatic burden and maximize quality of life.
Conclusion—Patient-centered, multidisciplinary care has a significant impact on the life of 
people with ALS and is the current standard of care for this patient population.
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Introduction
Amyotrophic lateral sclerosis (ALS, aka Lou Gehrig’s disease) is a daunting diagnosis to 
receive. The disease is uniformly fatal, with an average life expectancy of only three years 
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after symptom onset (Chio, Logroscino, et al., 2009; Miller, Mitchell, & Moore, 2012). The 
only FDA-approved treatment, riluzole, only confers a modest survival advantage (Miller, et 
al., 2012). The natural history of the disease is characterized by a relentlessly progressive 
course that is characterized by diffuse weakness and skeletal muscle wasting, and frequently 
accompanied by dysarthria, dysphagia, and failure of the muscles that support ventilation 
(Brooks, 1996). However an “atypical” disease presentation may occur, with much slower 
disease progression occurring in some individuals with about 10% of cases living 10 years 
or longer (Chio, Logroscino, et al., 2009). Thus, the severity of the illness and uncertainties 
regarding the time course of disability and evolving care burden are a cause of great stress 
for affected individuals and their families. Receiving a diagnosis of ALS is a life-changing 
experience for all people involved and health-care providers themselves are not immune 
from the enormity of the task of caring for these individuals (Bromberg, Schenkenberg, & 
Brownell, 2011). The clinical care for ALS is optimally centered around “ALS clinics” with 
disease-focused expertise offering a multi-disciplinary approach that leverages the 
experience of several health care providers such as neurologists, physiatrists, 
pulmonologists, physiotherapists, occupational therapists, speech and language pathologists, 
and assistive technology experts, to name a few (Mayadev, Weiss, Distad, Krivickas, & 
Carter, 2008). The role of the ALS specialist is multi-faceted and includes ownership of 
multiple aspects of care as well as delegation to sub-specialists and coordination of their 
services. This highly integrated, comprehensive care that keeps the person with ALS at the 
center of attention (Figure 1) has been shown to result in better quality of life, increased 
utilization of supportive care services, and possibly prolonged survival (Chio, Bottacchi, 
Buffa, Mutani, & Mora, 2006; Miller et al., 2009b; Traynor, Alexander, Corr, Frost, & 
Hardiman, 2003; Van den Berg et al., 2005; Zoccolella et al., 2007). Multidisciplinary care is 
now considered standard of care and is one of the eleven AAN-endorsed ALS quality 
measures (Miller et al., 2014). Despite the fatal outcome of the disease process, ALS 
multidisciplinary care is intrinsically “rehabilitative” where rehabilitation is defined as the 
process of assisting people to reach their fullest potential despite the presence of a disability. 
Therefore, in ALS, the goal of the doctor-patient relationship shifts from “cure” to “care”. 
The disease, while “incurable”, is clearly worth treating, and invites as much creativity as 
possible to enhance function throughout the course of a disease that is quite dynamic and 
diverse. This paper will discuss relevant aspects of rehabilitative care across the ALS 
spectrum, emphasizing issues that frequently arise in caring for this patient population and 
what the rehabilitation team can offer to assist patients as the disease progresses.
From symptom onset to diagnosis
Do I have ALS?
The onset of ALS is insidious and may “mimic” a variety of other conditions, often leading 
to misclassification and delays in diagnosis (Paganoni et al., 2014). The time from symptom 
onset to confirmed diagnosis ranges from 8 to 15 months (Cellura, Spataro, Taiello, & La 
Bella, 2012; Chio, 1999; Chio, Mora, et al., 2009; Donaghy, Dick, Hardiman, & Patterson, 
2008; Househam & Swash, 2000; Mitchell et al., 2010; Paganoni, et al., 2014), which 
represents a significant proportion of total disease duration. This “diagnostic delay” may 
include a period of time when the diagnosis was suspected (Paganoni, et al., 2014), but the 
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physician may have decided to delay discussion while ruling out mimickers or waiting for 
confirmation from an ALS specialist.
There is no consensus on how or when to deliver the diagnosis of ALS (Miller, et al., 
2009b). Small studies have highlighted that, unfortunately, many patients and their families 
are dissatisfied with diagnosis delivery (Borasio, Sloan, & Pongratz, 1998; McCluskey, 
Casarett, & Siderowf, 2004) and that better training in delivering challenging diagnoses is 
needed during medical education (Schellenberg, Schofield, Fang, & Johnston, 2014). 
Importantly, clinical experience supports the view that the way the diagnosis is 
communicated is the very first step in the rehabilitative process as it will have a major 
bearing on patient attitudes towards the disease and the medical team’s recommendations 
(Silani & Borasio, 1999). Establishing a good physician-patient relationship even before the 
diagnosis is confirmed may help reduce patients’ fears and dispel misconceptions such as 
“there is nothing that one can do” or the outcome of ALS is “choking to death” (Maessen et 
al., 2010). The peri-diagnostic time represents a unique opportunity to adjust to the 
diagnosis in a stepwise fashion, understand the evolving tools for care and research that the 
medical system offers as well as discover the many opportunities for involvement with 
patient support groups, advocacy and community resources.
Spending enough time discussing the diagnosis has been identified as a predictor of higher 
patient and caregiver satisfaction (McCluskey, et al., 2004). Patient surveys have also 
suggested that communication skills such as an empathetic style, delivering the diagnosis 
when the patient’s support network is present, arranging a short-term follow-up meeting to 
address additional questions or concerns, and informing patients of sources for help and 
support including tertiary care centers and clinical trial options are associated with positive 
patient feedback (Borasio, et al., 1998; McCluskey, et al., 2004). While diagnosis delivery 
cannot be standardized, research in cancer has developed various protocols to aid the 
clinician in this challenging task such as the SPIKES method (Baile et al., 2000). The goals 
of this strategy are to gather information from the patient to gauge knowledge and 
expectations, provide intelligible information and support, and develop a plan (Baile, et al., 
2000). These goals are achieved by using a variety of methods that are applicable to ALS as 
well (Baile, et al., 2000). Examples include choosing an appropriate setting (private room, 
with significant others present, sitting down with no barriers between clinician and patient), 
allowing enough time with no interruptions, asking open-ended questions to assess patient’s 
perceptions (“What have you been told about your medical condition so far?”), providing 
information in a stepwise fashion using non-technical terms (“Based on the tests we have 
done, there is a problem with your nerves so that your muscles can’t work properly”; “This 
condition is called amyotrophic lateral sclerosis”; “There is no cure at the moment although 
one drug is available to slow down the disease; there is also a lot of research going on at this 
time to try to find new treatments”), addressing patient’s emotions with empathetic 
responses (“I know this is not good news and I also wish the news were better”), and 
forming a strategy to go forward (“We have an experienced team here who works with many 
people with your same condition”; “We have multiple ideas and strategies to assist you 
through this”; “Your main problem at this time is ankle weakness and falls, we can help with 
this”). Finally, variability in disease progression should be discussed as some people with 
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ALS do have a slow progression and physicians’ ability to predict survival times is limited 
(Chio, Logroscino, et al., 2009; Kuffner et al., 2015).
Early ALS: exercise and adaptive equipment
Early symptoms of ALS can be quite variable. ALS can first develop in the legs or the arms 
or the bulbar region, with each region accounting for about a third of presentations. The 
onset is usually focal. The disease then progresses and spreads to other body regions. 
Typical presenting symptoms include ankle weakness causing foot drop, falls, difficulties 
with grip and fine motor skills, and slurred speech.
“Can exercise make me stronger?”
Many people with ALS ask about the role of exercise either because exercise has been an 
integral component of their pre-morbid lifestyle or because exercise is often thought to be 
reparative, having positive effects on endurance and strength. When they ask about exercise, 
most patients refer to aerobic training and strengthening programs.
The evidence regarding the risks and benefits of aerobic / strengthening exercise in ALS is 
limited to some pre-clinical evidence and two small clinical studies (Dal Bello-Haas & 
Florence, 2013). In mouse models of ALS, moderate endurance exercise delayed disease 
onset and increased survival (Carreras et al., 2010; Kirkinezos, Hernandez, Bradley, & 
Moraes, 2003; Veldink et al., 2003). High-intensity endurance training, on the other hand, 
was detrimental (Carreras, et al., 2010; Mahoney, Rodriguez, Devries, Yasuda, & 
Tarnopolsky, 2004). Small studies in people with ALS, also supported the safety of 
moderate-intensity exercise. In a study by Drory and colleagues (Drory, Goltsman, Reznik, 
Mosek, & Korczyn, 2001), 25 people with ALS were randomized to perform an 
individualized moderate-intensity daily exercise program “involving most muscle groups of 
the four limbs and trunk”, as opposed to avoiding any physical activity beyond their usual 
daily requirements. The goal of the program was to improve muscle endurance by “having 
the muscles work against only modest loads but undergo significant changes in length” 
(Drory, et al., 2001). The program was well tolerated and was associated with less functional 
decline on the ALS Functional Rating Scale (ALSFRS) and the Ashworth spasticity scale in 
the exercising group at 3 months following study initiation (Drory, et al., 2001). A second 
randomized, controlled trial of moderate resistance exercise in 27 people with ALS also 
resulted in better function at 6 months, as measured by total ALSFRS scores and quality of 
life, without adverse effects (Bello-Haas et al., 2007).
Currently there is an ongoing, larger trial of exercise in ALS to confirm and expand on these 
findings (NCT01521728). In the meantime, based on the available evidence so far and 
drawing from the exercise literature in other progressive neuromuscular diseases, we can 
conclude that moderate-intensity exercise is safe for people with ALS. Overexertion with 
resulting prolonged post-exercise fatigue, muscle pain, or soreness, however, should be 
avoided as these symptoms can signal overwork-induced muscle damage (Petrof, 1998). 
Exercise is unlikely to make muscles significantly stronger in ALS and high-intensity weight 
training in the gym should be discouraged. On the other hand, gentle, restorative exercise 
can be used as a tool to avoid further deconditioning and as a means to improve sleep and 
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mood. Aerobic exercise practiced in a community setting (e.g., accessible pool, adaptive 
golf, chair yoga, tai chi) is generally preferred and can also help promote social interactions. 
Practical recommendations for exercise in ALS are listed in Table 1. Of note, stretching and 
range-of-motion exercises should be encouraged starting early in the course of the disease 
and as part of a gentle, wellness-oriented, physical activity daily routine. Clinical experience 
suggests that performing simple stretching exercises that target the major joints helps 
prevent development of painful and function-limiting contractures, especially at the 
shoulders. Training with a physical therapist who will develop an appropriate exercise 
routine is recommended and periodic program modification will be needed as the disease 
progresses.
“I want to continue to work, take care of my children, go on a trip. What can you do to 
make this possible?”
As patients develop weakness in the bulbar, cervical, and/or lumbosacral regions, they lose 
the ability to perform the daily activities they care about. The focus of clinic visits should 
shift from documenting the inevitable progression of the weakness to pro-active 
brainstorming with all the members of the multidisciplinary team to find ways to make 
desired activities possible for as long as possible. Assistive devices and adaptive equipment 
should be considered and periodically re-evaluated. Some devices may be borrowed from 
patient support groups as they are expensive (Connolly et al., 2014; Gladman, Dharamshi, & 
Zinman, 2014) and multiple devices are likely to be needed along the course of disease 
progression (Bromberg, Brownell, Forshew, & Swenson, 2010). Of note, the introduction of 
these devices is sometimes viewed by patient’s as a sign of “defeat”. It is important that the 
rehabilitation team focus on the function-expanding aspect of assistive devices; these are the 
tools that will ensure that one can continue to enjoy functional independence and safe 
mobility at home, at work, and in the community for as long as possible.
Lower body weakness leads to a less efficient and more energy-consuming gait pattern 
(Menotti et al., 2011) as the patient needs to compensate for muscle imbalances to avoid 
tripping and falling. Proximal leg weakness may compound the problem, making it difficult 
to get out of a car or rise from a low surface. Further, muscle imbalance and compensatory 
gait patterns (e.g., steppage, hip hiking) can trigger musculoskeletal pain such as low back 
pain and can worsen fatigue. Braces and adaptive equipment are very valuable even early on 
to help prevent or manage these problems. Braces can be used on an intermittent basis when 
weakness is mild to help conserve energy (Bean, Walsh, & Frontera, 2001) and assist at 
times of demanding activities such as walking long distances. Several braces for the lower 
limbs are available. The most commonly used braces in ALS are ankle-foot-orthoses 
(AFOs), preferably light-weight and customized. As disease progresses, AFOs may be 
needed at all times to help reduce the risk of falling.
Adaptive equipment such as swivel cushions and lift chairs can help assist sit-to-stand 
transitions. Eventually, patients will need mobility aids such as canes, walkers, and 
wheelchairs. Canes provide the least stability and are appropriate for mild lower extremity 
weakness only, adding some proprioceptive input. Walkers provide the most support for the 
ambulant but weak patient, but are often perceived as cumbersome. Crutches have very 
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limited use in ALS, as one needs a high degree of upper body strength to use them. 
Transitioning to a wheelchair may be challenging both psychologically and logistically. It is 
important that wheelchairs are presented as a way to allow greater safety and independence 
such as during holiday trips and when attending social events. Manual and transport 
wheelchairs are useful in the early stages to help conserve energy especially when traveling 
long distances. However, power wheelchairs ultimately prove more useful as ALS patients 
develop upper body weakness that prevents them from propelling manual wheelchairs. Due 
to difficulties in obtaining insurance reimbursement for more than one wheelchair, it is 
recommended that ALS patients rent or borrow a manual or transport wheelchair instead of 
purchasing one. Insurance coverage should be reserved for the expensive (Ward et al., 2010), 
customized power wheelchairs. Proper seating and positioning in the wheelchair are critical 
to ensure comfort and prevent secondary problems such as skin breakdown and back pain. 
Thus, customization of the power wheelchair, teaching pressure relief maneuvers to patients 
and their caregivers, and providing ongoing monitoring and wheelchair adjustments in a 
clinic with experience with ALS is crucial for health and comfort.
Adaptive tools are also available to assist upper body weakness (Dal Bello-Haas, Kloos, & 
Mitsumoto, 1998). Fine motor skills are often affected first and patients complain of 
difficulties with doorknobs, buttons, zippers, cans, and jars. Occupational therapists (OTs) 
with experience in ALS may help guide patients to select among several pieces of adaptive 
equipment (Table 2). Hand splints may also be considered to compensate for intrinsic hand 
muscle weakness (Ivy, Smith, & Materi, 2014; Tanaka, Saura, Houraiya, & Tanimura, 2009). 
The goal of these devices is to allow the patient to get dressed and eat independently, read, 
write and use computers.
Symptom management as ALS progresses: medications and assistive 
technology
“What medications are available to control ALS-related symptoms?”
While we cannot change the ultimate outcome of the disease, there is certainly a lot that can 
be done to effectively manage ALS-related symptoms and maximize quality of life (Table 
3).
Pain—The classic tagline is that ALS is a disease characterized by “painless, progressive 
weakness”. While this is true with respect to the primary disease process, pain can develop 
as a secondary complication of musculoskeletal dysfunction due to limited mobility, loss of 
range of motion, and difficulty with positioning in bed or in a wheelchair (Boninger et al., 
2003; Gibson & Frank, 2005). Many people with ALS report pain even in the early stages of 
their disease (Pizzimenti, Aragona, Onesti, & Inghilleri, 2013; Rivera et al., 2013) and pain 
is associated with reduced quality of life (Pizzimenti, et al., 2013). Common sites of pain 
include the low back, the neck, and the shoulder region (Ho, Ruthazer, & Russell, 2011). 
Surprisingly, pain in ALS has been poorly studied and is often poorly managed (Wallace et 
al., 2014). This is very unfortunate as many causes of pain can be prevented and/or managed 
by simple interventions such as providing adequate lumbar support or adjusting the arm rests 
of the patient’s wheelchair. For power wheelchair users, power elevating the legs can ease 
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back pain and the tilt-in-space feature helps relieve pain from gluteal pressure. Braces and 
splints can support joints that are affected by progressive muscle weakness. For example, 
many people with ALS develop shoulder pain due to loss of strength of the peri-scapular 
musculature with subsequent loss of range of motion, subluxation, and development of 
contractures. A regular stretching program, combined with the use of shoulder 
approximation sleeves, can help prevent shoulder pain. In the legs, discomfort can be 
compounded by dependent edema which can benefit from leg elevation, massage, and 
compression stockings.
Physical medicine modalities can help relieve pain in many patients (Table 3) (Gaujoux-
Viala, Dougados, & Gossec, 2009; Gracies, 2001; Green, Buchbinder, & Hetrick, 2003, 
2005). Pharmacologic treatment of pain may also be needed using one or more of several 
agents. The choice of the specific compound is based on clinician experience as there has 
been no trials of drug therapy for pain in ALS (Brettschneider, Kurent, & Ludolph, 2013). 
Options include non-steroidal anti-inflammatory medications (NSAIDs), acetaminophen and 
medications for neuropathic pain. Opioids may be needed, especially in advanced disease 
(Oliver et al., 2010).
Spasticity—Management of spasticity in ALS has been poorly studied; however, several 
agents are available for use including baclofen, tizanidine, benzodiazepines, and 
cannabinoids. The choice of one agent vs. another is based on experience, side effect profile, 
and patient response. Intrathecal baclofen, and botulinum toxin can be considered in primary 
lateral sclerosis (PLS) and select cases of upper-motor neuron predominant ALS. Of note, 
reduction of bothersome spasticity needs to be balanced with the fact that some increased 
tone in certain muscle groups can actually support function (e.g., spasticity in the extensor 
muscles of the legs can assist standing during transfers and facilitate bed mobility). Non-
pharmacologic treatment options for spasticity can be offered as an adjunct, although the 
effects of such interventions are generally limited and temporary (Table 3) (Gracies, 2001).
Cramps—Cramps can be quite bothersome in ALS and yet management of cramps has 
been understudied in ALS (Baldinger, Katzberg, & Weber, 2012; Miller, et al., 2009b). 
Quinine has been used in the past with some success (El-Tawil et al., 2010), but due to the 
potential for serious hematologic reactions (Houstoun et al., 2014), quinine treatment for leg 
cramps has decreased significantly and is not approved by the Food and Drug 
Administration (FDA) for this use. However, in our experience some people with ALS will 
drink tonic water to relieve cramps as it contains some quinine. Regardless, concerns about 
potential quinine-related side effects remain, thus limiting its usefulness. Empirically, many 
ALS clinicians try one of several medications to address cramps including baclofen, 
gabapentin and cannabinoids (Weber, Goldman, & Truniger, 2010) with variable success. 
Additional agents with potential benefit include vitamin B and diltiazem (Katzberg, Khan, & 
So, 2010) as well as levetiracetam (Bedlack, Pastula, Hawes, & Heydt, 2009). Stretching, 
gentle exercise (Ribeiro, 2014) and good hydration may also be beneficial. A trial of 
mexiletine for the treatment of muscle cramps in ALS is ongoing (NCT01811355).
Sialorrhea / secretion management—Drooling of saliva occurs in ALS due to oro-
pharyngeal weakness that also leads to difficulty expectorating sputum and bronchial 
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secretions. Patients may be bothered by saliva leaking from the corner of the mouth while at 
the same time they have the feeling that some dry, thick secretions are “stuck in the back of 
the throat”. This combination of symptoms may be extremely frustrating for patients and 
may be difficult to manage as finding the right balance between too much drooling and too 
much “dryness” can be tricky.
Pharmacological agents for sialorrhea management are listed in Table 3 and are available in 
different formulations (Banfi et al., 2014). Their use is limited by anticholinergic side effects 
such as constipation, difficulty urinating, dry eyes, blurred vision, and confusion. Botulinum 
toxin injection (Anagnostou et al., 2013; Jackson et al., 2009; Stokholm, Bisgard, & 
Vilholm, 2013) and radiation (Assouline et al., 2014; Kasarskis, Hodskins, & St Clair, 2011) 
of the salivary glands are alternative strategies that can be considered when adequate 
symptom control cannot be achieved or is limited by intolerable side effects caused by use of 
systemic agents. These interventions can be quite effective and have few side effects, 
although rapid worsening of dysphagia to the point of requiring insertion of a gastrostomy 
tube is a potential rare complication of botulinum toxin injection.
Treatment of sialorrhea can make clearance of bronchial secretions more difficult by 
increasing their viscosity. Mucolytics can be used to counteract this problem. In addition, 
cough assist devices are widely used to promote airway clearance and are recommended 
treatment when the patient’s peak cough flow is measured at 270L/min or less during routine 
pulmonary function testing.
Fatigue and sleep—Fatigue is a frequently reported symptom in ALS (McElhiney, 
Rabkin, Gordon, Goetz, & Mitsumoto, 2009a; Ramirez, Piemonte, Callegaro, & Da Silva, 
2008) and is a disabling problem for many. The term “fatigue” refers to both an inability to 
sustain motor function during exertion and a pervasive tiredness (Gibbons, Thornton, & 
Young, 2013). Causes of fatigue are multiple, ranging from nocturnal hypoventilation with 
resulting excessive daytime sleepiness to uncontrolled pain and cramps that interfere with 
sleep (Lo Coco & La Bella, 2012). Behavioral and medical interventions that may aid in 
fatigue management are listed in Table 3. Modafinil has been proposed as a pharmacologic 
treatment for fatigue in ALS based on two small studies (Carter et al., 2005; J. G. Rabkin et 
al., 2009), but cost is a limiting factor and confirmation of efficacy is needed in larger 
studies.
“The worst part of ALS is that I lost my ability to communicate”
Dysarthria and the prospect of losing the ability to communicate are understandably 
frightening symptoms for people with ALS. Reduced speaking rate often precedes loss of 
intelligibility (Yunusova et al., 2012; Yunusova et al., 2010). Unfortunately, oral motor 
exercises are not likely to help and, in fact, many people with ALS report worsening of their 
speech the longer they talk. Speech therapy, however, can teach people to develop 
compensatory techniques such as minimizing the distance to the listeners, speaking face-to-
face in a well lit room, overarticulating, and spelling out words. Taking rest breaks before 
speaking engagements can help to maximize speaking endurance.
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As dysarthria progresses, augmentative and alternative communication (AAC) devices such 
as text-to-speech devices and computer / tablet applications for speech production are 
needed (Brownlee & Palovcak, 2007). AAC use is associated with improved quality of life 
and mood in people with severe dysarthria / anarthria (Caligari, Godi, Guglielmetti, 
Franchignoni, & Nardone, 2013; Korner et al., 2013). Message (voice) banking allows 
people to record their own voice and play it back on speech devices. These devices can be 
operated manually, by eye gaze (Caligari, et al., 2013; Spataro, Ciriacono, Manno, & La 
Bella, 2014), or by head movement tracking technology, allowing communication to occur 
even in the later stages of the disease (Caligari, et al., 2013). Even for patients who use AAC 
effectively, however, it important to develop personalized communication strategies with the 
caregivers such as a system for quickly confirming understanding or asking for help. Finally, 
brain-computer interfaces (BCIs) are an active area of research. BCIs transform brain signals 
(Collinger et al., 2013; Hochberg et al., 2012; Sellers, Ryan, & Hauser, 2014; Simeral, Kim, 
Black, Donoghue, & Hochberg, 2011) into commands that activate and move a cursor or a 
switch and are currently being evaluated for use in ALS (Huggins, Wren, & Gruis, 2011; 
McCane et al., 2014; Nijboer et al., 2008).
“Why do I cough when I eat?”
Coughing at mealtimes, frequent throat clearing, wet vocal quality, feeling that food gets 
“stuck”, and choking are all symptoms of oropharyngeal and tongue weakness leading to 
dysphagia. Dysphagia can lead to aspiration and malnutrition, a negative prognostic factor in 
ALS (Desport et al., 1999; Paganoni, Deng, Jaffa, Cudkowicz, & Wills, 2011). As 
development of dysphagia is expected in ALS, bedside assessment of swallowing by a 
speech and language pathologist (SLP) is generally enough, although Modified Barium 
Swallow (MBS) may be considered to help educate patients on compensatory swallowing 
strategies and behavioral changes (e.g., head tilt, chin tuck, alternating bites of solid food 
with sips of liquid). Patients also need to be trained on diet modifications that can promote 
safe swallowing such as favoring soft, moist foods over dry, crumbly, or chewy foods. 
Neuromuscular dysphagia generally begins with difficulty managing liquids. Therefore, even 
in the early stages of the disease switching to thicker liquids (fruit nectar, smoothies) or 
addition of commercially available thickeners may be needed.
When oral intake becomes inadequate, too effortful or fatiguing, and/or compromises safety, 
alternative routes for nutrition may be considered to stabilize body weight (Miller et al., 
2009a) and, possibly, prolong survival, although the effect on survival is still debated 
(Atassi, Cudkowicz, & Schoenfeld, 2011; Miller, et al., 2009a). These methods include 
percutaneous endoscopic gastrostomy (PEG) and radiologically inserted gastrostomy (RIG), 
with the latter being safer in ALS (Allen et al., 2013). The risk of gastrostomy tube 
placement increases when forced vital capacity falls below 50% of predicted (Miller, et al., 
2009a). Therefore, early intervention is practiced by many although the best timing for 
performing the procedure is unknown (Miller, et al., 2009a).
“I cannot lie flat”
Failure of the muscles that support ventilation is the leading cause of death in ALS. 
Diaphragm weakness first manifests as nocturnal hypoventilation and may lead to 
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interrupted sleep, increased anxiety, early morning headaches, and excessive daytime 
fatigue. As disease progresses, patients develop orthopnea with inability to lie flat, dyspnea 
on exertion and eventually shortness of breath when sitting. Weak cough and difficulty 
clearing secretions are associated symptoms. Patients may also develop a soft voice as 
sufficient respiratory support is needed to speak loudly.
Most patients with ALS remain asymptomatic until their vital capacity (VC) is less than 
50% of predicted. VC correlates with survival (Traynor, Zhang, Shefner, Schoenfeld, & 
Cudkowicz, 2004), is employed in clinical trials as an outcome measure and is routinely 
monitored using portable spirometers in most ALS clinics (Miller, et al., 2009a). Additional 
and probably more sensitive methods to monitor diaphragm weakness include nocturnal 
oximetry, supine VC, maximal inspiratory pressure (MIP), and sniff nasal pressure (SNP) 
(Miller, et al., 2009a). These methods are available in many centers although VC remains the 
most commonly used measure.
When patients develop symptoms or their VC falls below 50%, non-invasive positive 
pressure ventilation (NIPPV) is offered to support ventilation, initially at night, and then 
during daytime naps or longer as needed (Miller, et al., 2009a). Discussion about the natural 
course of breathing difficulties in ALS should be initiated early after diagnosis, so that 
patients can learn about the benefits and limitations of all forms of assistive ventilation and 
make informed choices. A randomized controlled study from 2006 showed that NIV was 
effective at prolonging survival in people with ALS, with a median survival benefit of 205 
days (Bourke et al., 2006). This benefit, however, was not seen in patients with poor bulbar 
function (Bourke, et al., 2006). NIV also improved quality of life and sleep-related 
symptoms, even when bulbar dysfunction was present (Bourke, et al., 2006). Based on this 
trial, and a few other subsequent observational studies, NIV is now considered part of the 
standard of care for ALS, although its use may be limited by patient acceptance and 
compliance (Miller, et al., 2009a). Diaphragm pacing is a newer, alternative means of 
supporting ventilation. Its effectiveness in prolonging survival in ALS, however, is unclear at 
this time (Gonzalez-Bermejo et al., 2012; Mahajan, Bach, Saporito, & Perez, 2012; Onders, 
Elmo, Kaplan, Katirji, & Schilz, 2014) and is the subject of ongoing research (McDermott et 
al., 2012). Additional preventive interventions include influenza and pneumococcal 
vaccination that are recommended for all people with ALS. Supplemental oxygen is rarely 
used unless there is concurrent pulmonary disease as it may suppress respiratory drive and 
lead to carbon dioxide retention. Finally, some people with ALS choose tracheostomy and 
invasive mechanical ventilation to prolong life (Dreyer, Lorenzen, Schou, & Felding, 2014). 
This practice is frequent in some countries (Fini et al., 2014; Tagami et al., 2014), but chosen 
by only a minority in the United States (J. Rabkin et al., 2013).
Psychological health and quality of life
People with amyotrophic lateral sclerosis (ALS) face enormous physical and emotional 
challenges. It is therefore expected for ALS to have a psychological impact on patients both 
at the time of diagnosis and throughout the course of the disease (Atassi et al., 2011; Cupp et 
al., 2011; Felgoise et al., 2010; Kurt, Nijboer, Matuz, & Kubler, 2007; McElhiney, Rabkin, 
Gordon, Goetz, & Mitsumoto, 2009b; J. G. Rabkin et al., 2005; Tedman, Young, & 
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Williams, 1997; Wicks et al., 2007). Interestingly, prior studies have shown that 
psychological distress is not directly related to functional impairment (Atassi, Cook, et al., 
2011; Cupp, et al., 2011; McElhiney, et al., 2009b; J. G. Rabkin, Wagner, & Del Bene, 
2000). It has been speculated that in ALS the predicted functional losses lead the patient to 
change his or her health expectations (Cupp, et al., 2011). Changes in expectations may be 
accompanied by a response shift so that the factors that contribute most to psychological 
health shift from those that are dependent on physical function to those that are not (social, 
spiritual, and existential factors) (Cupp, et al., 2011; Lule et al., 2009). Perceived social 
support is a strong predictor of psychosocial adjustment (Lule, et al., 2009).
Still, mildly-to-severely depressed mood is present in 10–56% of people with ALS, with 
prevalence varying greatly depending on the scale used to define depression (Atassi, Cook, 
et al., 2011; Cupp, et al., 2011; Felgoise, et al., 2010; Kurt, et al., 2007; McElhiney, et al., 
2009b; J. G. Rabkin, et al., 2005; Tedman, et al., 1997; Wicks, et al., 2007). When present, 
depression can be effectively treated with a combination of pharmacological treatments and 
cognitive-behavioral interventions (Table 3). An additional, disabling symptom is 
pseudobulbar affect (PBA), characterized by excessive laughing or crying incongruous to 
circumstances. This problem affects 20%–50% of people with ALS and responds well to the 
combination of dextromethorphan and quinidine (Brooks et al., 2004; Pioro et al., 2010; 
Yang & Deeks, 2015). Although PBA is not a mood disorder, antidepressants are also 
frequently employed and can be effective. Interestingly, wish to die does not correlate with 
depression (Albert et al., 2005; J. G. Rabkin et al., 2014), pain (Maessen, et al., 2010), or 
inadequate care (Maessen, et al., 2010). Rather, wish to die is linked to hopelessness, fear of 
suffocation, and fear of being a burden (Albert, et al., 2005; Lule et al., 2014; Maessen et al., 
2009; Maessen, et al., 2010).
Multiple studies have shown that quality of life (QOL) is maintained as ALS progresses 
(Gauthier et al., 2007; Rousseau, Pietra, Blaya, & Catala, 2011; Rousseau, Pietra, Nadji, & 
Billette de Villemeur, 2013) and that QOL does not directly correlate with strength and 
physical function (Chio et al., 2004; Grehl, Rupp, Budde, Tegenthoff, & Fangerau, 2011; 
Simmons, Bremer, Robbins, Walsh, & Fischer, 2000). Rather, quality of life depends 
primarily on psychological and existential factors (Bremer, Simone, Walsh, Simmons, & 
Felgoise, 2004; Calvo et al., 2011; Chio, et al., 2004; Simmons, et al., 2000). Interestingly, 
the QOL of people with ALS is often underestimated by caregivers and healthcare 
professionals (Lule et al., 2013; Trail, Nelson, Van, Appel, & Lai, 2003).
Advanced disease and end-of-life care
Early involvement of palliative care as part of the multidisciplinary team ensures an 
integrated approach across the spectrum of the illness that includes multi-modal symptom 
management, advanced planning of end-of-life care, and timely utilization of hospice (Bede 
et al., 2011; Blackhall, 2012; Karam, Paganoni, Joyce, Carter, & Bedlack, 2014). Patients 
with advanced disease and their caregivers face increasing physical, financial, and emotional 
demands (Chio, Gauthier, Calvo, Ghiglione, & Mutani, 2005; Connolly, et al., 2014; 
Gauthier, et al., 2007; Gladman, et al., 2014; Lillo, Mioshi, & Hodges, 2012; Qutub, 
Lacomis, Albert, & Feingold, 2014). Adequate social support is associated with reduced 
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burden (Pagnini et al., 2010; Qutub, et al., 2014) and continued engagement with the 
multidisciplinary team assists patients and their caregivers in coping with worsening 
functional status. Home visits and telemedicine visits reduce the need for logistically 
difficult trips to the ALS clinic (Vitacca et al., 2010). The main focus of palliative care for 
people with advanced ALS is proactive management of symptoms such as pain and 
shortness of breath, which can be effectively managed with a variety of medications 
including opioids and benzodiazepines (Oliver, et al., 2010), coordination of home care 
services, and caregiver support.
Research and future directions
Basic ALS research has seen several breakthrough discoveries in recent years including a 
novel understanding of the genetic complexities and molecular mechanisms of the disease 
(Renton, Chio, & Traynor, 2014; Turner et al., 2013). While the lack of disease-modifying 
treatments at this time is upsetting, one should keep in mind that the pace of discovery in 
ALS has greatly accelerated over the last 20 years (Figure 2). Little progress was made 
between the original description of ALS in the 19th century and 1993, the year that the first 
ALS-causing gene was discovered. On the other hand, over the last two decades, there has 
been an exploding interest in ALS genetics, pre-clinical modeling, and pathophysiology. 
Hope for ALS is fostered by a vibrant patient community with high involvement with 
research (Chad et al., 2013) and fundraising (Vaidya, 2014) as well as by a collaborative 
clinical research community that has developed infrastructure resources, shared metrics, and 
a roadmap to optimize translational research (Atassi et al., 2013; Beghi et al., 2011; 
Cudkowicz et al., 2010; Otto et al., 2012; Sherman et al., 2013). Admittedly, the recent 
exciting basic science discoveries have yet to translate into effective treatments for patients. 
However, they have already led to a large pipeline of potential therapies that await testing in 
clinical trials. The hope is that this momentum will soon translate into new treatments for 
ALS.
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A model of person-centered multidisciplinary network of care
Abbreviations: MD: medical doctor; PT: physical therapist; OT: occupational therapist; RT: 
respiratory therapist; SLP: speech and language pathologist.
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Timeline of ALS research
Abbreviations: C9orf72: chromosome 9 open reading frame 72; iPSC: induced pluripotent 
stem cells; SOD1: copper zinc superoxide dismutase 1; TDP-43: TAR DNA-binding protein 
43.
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Table 1
Practical, empiric recommendations for exercise in ALS
Type of
exercise
Potential benefits Practical considerations
Flexibility Prevention and management of
contractures; might also help
reduce pain and spasticity
Start early in the disease course and incorporate in
gentle daily routine with caregiver participation as
needed.
Strengthening Potential role in maintaining
muscle strength




Progress as tolerated (“start low, go slow”).
Aerobic Potential role in reducing
deconditioning and improving
mood, sleep, spasticity and
quality of life
Perform at a moderate, sub-maximum level.
If the patient cannot talk comfortably during exercise,
the program is too vigorous.
Progress as tolerated (“start low, go slow”).
Consider community-based programs that encourage
social interaction and participation such as adaptive
sports program (e.g., adaptive golf).













Paganoni et al. Page 25
Table 2
Adaptive equipment for ADLs/IADLs.
Activity Example
Meal preparation and self-feeding Large-handled utensils or foam cylinders placed around utensils,
rocker knives, universal cuffs for holding utensils, long straws,
scoop dishes, nonskid pads, mobile arm supports
Dressing Button hooks, zipper pulls, Velcro fasteners, elastic shoelaces,
reachers, dressing sticks, long-handled shoe horns
Grooming and personal hygiene Strap-fitted hairbrush, long-handled comb and sponge, foam
cylinders placed around the handle of bath tools to facilitate grip
Reading and writing Page-turning devices, large-handled pens or foam cylinders placed
around pens to improve grip, hand splints
Abbreviations: ADLs: activities of daily living; IADLs: instrumental activities of daily living.

















Pain Physical medicine and rehabilitation strategies: optimization of transfers, seating and
positioning; bracing; physical therapy; stretching and gentle exercise; massage; TENS; ice
/heat; ultrasound; inontophoresis; acupuncture; trigger point injections; joint injections (with
lidocaine and steroids). Note that these strategies may be enough to effectively manage pain
in many patients with none to minimal side effects.
Medications: topical analgesics, acetaminophen, NSAIDs, gabapentin, pregabalin, opioids.
Spasticity Medications: baclofen, tizanidine, benzodiazepines, cannabinoids (ITB and botulinum toxin
in PLS and select cases of UMN-predominant ALS).
Adjunctive treatments: as above in the pain section, although the effect on spasticity is
limited and temporary.
Cramps Medications: baclofen, gabapentin, cannabinoids.
Adjunctive treatments: stretching, gentle exercise, hydration (tonic water).
Sialorrhea Medications: glycopyrrolate (may be used SC or IM in advanced disease),
amitriptyline, atropine drops (SL), scopolamine transdermal patch, hyoscyamine.





Most effective: cough-assist device.
Adjuncts: guaifenesin, N-acetylcysteine nebulizing treatment, good hydration.
Fatigue Screen for nocturnal hypoventilation and initiate NIV as needed.
Screen for co-morbidities such as anemia and malnutrition and correct if present.
Treat pain, cramps and spasticity that may interfere with sleep.
Review medication list for side effects.
Use braces and assistive devices to help conserve energy. Use energy conservation
techniques such as pacing and taking rest breaks.
? modafinil.
Depression SSRIs; SNRIs; bupropion; tricyclics.
Cognitive-behavioral therapy.
Abbreviations: ALS: amyotrophic lateral sclerosis; IM: intramuscular; ITB: intratechal baclofen; NIV: non-invasive ventilation; NSAIDs: non-
steroidal anti-inflammatory drugs; PLS: primary lateral sclerosis; SC: subcutaneous; SL: sublingual; SSRIs: selective serotonin reuptake inhibitors; 
SNRIs: serotonin norepinephrine reuptake inhibitors; TENS: transcutaneous electrical nerve stimulation; UMN: upper motor neuron.
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